Mosaic ImmunoEngineering Submits Application for Nasdaq Uplisting

June 28, 2021 7:00 AM

NOVATO, CA / ACCESSWIRE / June 28, 2021 / Mosaic ImmunoEngineering Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused on immunotherapies to treat and prevent cancer and infectious diseases through innate and adaptive immune activation, announced today that it has submitted its initial application to list the company's common stock on the Nasdaq Capital Market.The listing of Mosaic's shares on Nasdaq...

Read more

Biopharmaceutical Company Lands Feature in Popular Industry Publication With the Help of Newswire

June 25, 2021 10:15 AM

NEW YORK, NY / ACCESSWIRE / June 25, 2021 / A major component of a media and marketing communications strategy is securing valuable earned media opportunities to build brand awareness and connect with a company's target audience.At the end of March, Newswire was able to do just that for one of its Media and Marketing Guided Tour clients in the biopharmaceutical space by securing a feature story in a prominent industry publication.This feature...

Read more

Pieris Pharmaceuticals Announces Inhaled CTGF Inhibitor PRS-220 for Idiopathic Pulmonary Fibrosis and 17 Million Dollar Grant From Bavarian Government To Accelerate Program Development for Post-COVID-19 Pulmonary Fibrosis

June 25, 2021 7:00 AM

PRS-220, an oral inhaled Anticalin protein targeting CTGF, a fully proprietary drug candidate for respiratory disease, is being developed as a local treatment for idiopathic pulmonary fibrosisGrant to enable the evaluation of PRS-220 for the treatment of post-COVID-19-related pulmonary fibrosis for clinical-readiness in general and initial clinical development of PRS-220 in the post-COVID-19 settingClinical development of PRS-220 expected to...

Read more

Helix BioPharma Corp. Announces Appointment of New Auditor and Extends Period to Exercise Warrants

June 24, 2021 5:00 PM

RICHMOND HILL, ON / ACCESSWIRE / June 24, 2021 / Helix BioPharma Corp. (TSX:HBP) ('Helix' or the 'Company'), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has appointed Marcum LLP as the Company's new auditor, replacing BDO Canada LLP. The Company has filed a Notice of Change of Auditor in respect of this change under its SEDAR profile at www.sedar.com.The...

Read more

Pieris Pharmaceuticals Receives Orphan Drug Designation for Cinrebafusp Alfa for the Treatment of Gastric Cancer

June 24, 2021 8:00 AM

BOSTON, MA / ACCESSWIRE / June 24, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to cinrebafusp alfa (PRS-343), a 4-1BB/HER2 bispecific, for the treatment...

Read more

Edesa Biotech Team Expands Leadership Team with Key Manufacturing Appointment

June 23, 2021 7:55 AM

TORONTO, ON / ACCESSWIRE / June 23, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the appointment of a key member to its management team to support the company's expanding manufacturing activities.Rajan Puri has been appointed to the newly established position of Senior Vice President of Manufacturing. Mr. Puri is an expert in Chemistry,...

Read more

Pressure BioSciences to Present at the Emerging Growth Conference

June 22, 2021 7:47 AM

Company Invites Individual and Institutional Investors, as well as Analysts and Advisors, to Attend Its Real-Time, Interactive Presentation on Wednesday, June 23, 2021SOUTH EASTON, MA / ACCESSWIRE / June 22, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and services to the worldwide life sciences,...

Read more

Gary Herman Joins GB Sciences' Subsidiary GbS Global Biopharma as Advisory Director

June 22, 2021 7:00 AM

LAS VEGAS / ACCESSWIRE / June 22, 2021 / GB Sciences, Inc. (OTCQB:GBLX) announces that long-term investor Gary Herman has joined GbS Global Biopharma, Inc., its wholly owned Canadian subsidiary, as an Advisory Director. Herman has a strong investment background in growth companies in the cannabis, biopharma, and technology sectors.An experienced fund manager and investor who sits on several corporate boards, Herman brings over 20 years of...

Read more

Applied UV and FSG Sign Master Distributor Agreement

June 21, 2021 1:50 PM

MOUNT VERNON, NY / ACCESSWIRE / June 21, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced the signing of a Master Distributor agreement for the United States with FSG,...

Read more

Applied UV Receives Initial Purchase Orders in Excess of $850,000 from 3Sixty Biopharmaceuticals, its Exclusive Distributor for Airocide(R) Air Purification Systems for the Continent of Africa

June 18, 2021 8:30 AM

Initial order is part of $3.5 million minimum first year purchase commitment of Airocide® systemsMOUNT VERNON, NY / ACCESSWIRE / June 18, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and...

Read more

Edesa Biotech Reports Favorable Review of COVID-19 Study

June 18, 2021 7:45 AM

TORONTO, ON / ACCESSWIRE / June 18, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported that an independent Data and Safety Monitoring Board (DSMB) has completed an interim review of the company's COVID-19 drug candidate, and based on blinded comparative data, has recommended that the company's international study continue as planned.The safety...

Read more

Applied UV Announces Laboratory Results Confirm SteriLumen's Lumicide(TM) Ribbon Kills SARS-CoV-2 (COVID-19 Virus)

June 16, 2021 8:30 AM

Previously reported independent lab results confirmed killing OC43 human coronavirus ("OC43"), a common surrogate for SARS-CoV-2, the virus that causes COVID-19MOUNT VERNON, NY / ACCESSWIRE / June 16, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air...

Read more

Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States

June 15, 2021 10:00 PM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares ('ADSs') at a public offering price of $21.25 per ADS, for total gross proceeds of approximately $63.8 million....

Read more

Aqualung Therapeutics Plans A Phase 0 ARDS Trial for eNAMPT Monoclonal Antibody (Alt-100 mAb) Following Type B FDA Meeting

June 15, 2021 3:00 PM

Phase 0 trial in ARDS subjects estimated completion by end of 1st QTR 2022FDA indicates general agreement on required IND-enabling program for ALT-100 mAb in ARDS patientsALT-100 humanized mAb manufacturing initiated and speeding toward GMP completionTUCSON, AZ / ACCESSWIRE / June 15, 2021 / Aqualung Therapeutics Corp., a biotech company focused on the development of novel therapies to combat unchecked systemic inflammation, completed a...

Read more

Viewpoint Molecular Targeting(TM) Chief Scientific Officer, Dr. Michael Schultz, Discusses the Promise of Image-Guided 212Pb Alpha-Particle Radiopharmaceutical Therapies for Cancer at the SNMMI 2021 Annual Meeting

June 15, 2021 8:30 AM

Presented data highlights the performance of Viewpoint's chelation technologyCORALVILLE, IA / ACCESSWIRE / June 15, 2021 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced that Michael K. Schultz PhD, Chief Science Officer of Viewpoint presented at The Society of...

Read more

Oncology Pharma, Inc. Eyes Collaboration with Patent Opportunities Amongst Its Licensed Intellectual Properties

June 15, 2021 8:00 AM

SAN FRANCOSCO, CA / ACCESSWIRE / June 15, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the 'Company') has been continuing its research and work reviewing and implementing collaboration between its interests in therapy, delivery and trial experience amongst its licensed products. The Company is in the early stages of reviewing the work and exploring opportunities between the synergistic value of its licensed Intellectual...

Read more

Marble Arch Research Publishes Analyst Research Report on Nascent Biotech

June 15, 2021 8:00 AM

VERO BEACH, FL / ACCESSWIRE / June 15, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to highlight the publication of an in-depth analyst research report on Nascent Biotech by equity research firm, Marble Arch Research, Inc, which rated NBIO...

Read more

Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs

June 15, 2021 7:05 AM

DehydraTECH™ improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2KELOWNA, BC / ACCESSWIRE / June 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce positive results from its tolerability and pharmacokinetic ("PK") animal study VIRAL-A20-2, evaluating...

Read more

Mosaic ImmunoEngineering Inc. Elects Biotechnology Industry Veteran Robert A. Baffi, Ph.D. to Its Board of Directors

June 15, 2021 7:00 AM

Experience in the Development of Biotechnology and Viral Based Therapeutics Will Help Enhance the Development of the Company's PipelineNOVATO, CA / ACCESSWIRE / June 15, 2021 / Mosaic ImmunoEngineering Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases, today announced the...

Read more

RepliCel Adds Independent Director

June 15, 2021 6:00 AM

Board of Directors Strengthens Its Independence Oversight and Updates its Stock Options VANCOUVER, BC / ACCESSWIRE / June 15, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2), (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has appointed Gary Boddington to the board of directors.Gary Boddington is...

Read more